Quantum Genomics

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the research and development of drugs for the treatment of cardiovascular diseases. The company develops drugs primarily to treat high blood pressure and heart failure. Its research programs are based on the Brain Aminopeptidase A Inhibition, a triple action therapeutic platform, licensed from the academic research laboratories of the Collège de France, INSERM, and CNRS. The company’s research programs include QGC001, which is in phase IIa clinical trial to evaluate the safety and blood pressure effectiveness in patients with high blood pressure; and QGC011, which is in pre-clinical phase for the treatment of high blood pressure with combination therapy. It is also developing QGC006 to optimize the treatment of high blood pressure with a monotherapy drug; and QGC101, which is in pre-clinical phase for the prevention and treatment of heart failure. The company is based in Paris, France.

Paris, FR
Size (employees)
6 (est)
Quantum Genomics was founded in 2006 and is headquartered in Paris, FR

Quantum Genomics Office Locations

Quantum Genomics has an office in Paris
Paris, FR (HQ)
Tour Maine Montparnasse 33 Avenue du Maine
Show all (1)

Quantum Genomics Financials and Metrics

Quantum Genomics Financials


Market capitalization (31-Oct-2017)

28 m

Closing share price (31-Oct-2017)

Quantum Genomics's current market capitalization is €28 m.
Show all financial metrics

Quantum Genomics Market Value History

Quantum Genomics's Web-traffic and Trends

Quantum Genomics Online and Social Media Presence

Quantum Genomics Company Life and Culture

You may also be interested in